Nicole Brument

Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

Part of KBC Group NV, Thea Pharma NV is a Belgian pharmaceutical company that specializes in the treatment of eye diseases such as blepharitis, dry eyes, glaucoma, and age-related macular degeneration. The company is based in Wetteren, Belgium and was founded in 2000 by Henri Roger Pierre Chibret. Thea Pharma offers a range of products including medicines, medical devices, cosmetics, and dietary supplements. The company is committed to using fewer preservatives in their products and has expertise in the harmful effects of preservatives. Thea Pharma also has a foundation that supports various projects related to eye health.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT.

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.

Genzyme Genetics, Inc. provides laboratory testing and diagnostic services specifically for reproductive and oncology tests. It provides tests for cystic fibrosis carriers and cancers. The company is headquartered in Westborough, MA.

Théa Pharma GmbH is a research laboratory that specializes in eye health. The private company was founded in 1870 and is based in Berlin, Germany. The CEOs are Jean-Frédéric Chibret and Christoph Kessler. Théa Pharma offers a comprehensive range of treatment free of preservatives that takes into account the precious of the eye. The German company provides further training through its medical library and Théa Akademie online continuous training. Théa Pharma also offers products such as the EasyGrip® multi-dose bottle, which makes handling even more user-friendly, especially for the elderly. The company's anniversary brochure describes 150 years of ophthalmology history based on those of the Chibret family who carries ophthalmology in the genes.

Thea Holding operates as a investment company. The company is headquartered in Clermont-Ferrand, France.

Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.

Part of Thea Holding SAS, Thea Pharmaceuticals Ltd. is a British company that manufactures and distributes ophthalmic care products. The company is based in Newcastle-under-Lyme, UK. The company was founded in 2008. Thea Pharmaceuticals was acquired by Laboratoires Théa SAS from Vision Pharmaceuticals Ltd. on June 17, 2014.

Laboratoires Théa SAS manufactures and markets eye care products. The firm offers dry eyes, allergy, herpes and eye hygiene. The company was founded by Henri Chibret in 1994 and is headquartered in Clermont-Ferrand, France.

Part of V-Bio Ventures BV, V-Bio Management 1 BV functions as an investment holding Belgian company. The company is based in Ghent, Belgium.

V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

Altamar Private Equity SGIIC SA (Altamar Private Equity) is a private equity arm of Altamar Capital Partners SL founded in 2004. The firm is headquartered in Spain with additional offices in New York and Santiago de Chile.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France.

The French-American Chamber of Commerce (FACC) is a non-profit, member-driven organization founded in 1985. The non-profit company is based in Atlanta, GA. The FACC is part of a network of 18 French-American chambers representing over 5,000 companies nationwide in all major industries. The company is also a proud member of CCI International, an international network of 124 French chambers of commerce in 95 countries, representing over 37,000 members worldwide. The FACC's mission is to promote, support, and enhance business opportunities among the French-American business community throughout the Southeast of the United States. The company provides opportunities for members to network, connect, collaborate, and learn from one another through events and programs. The FACC is the main professional forum and business resource for French companies and their leaders doing business in and with the Southeast of the United States, and for companies in the Southeast of the United States doing business in and with France. The company also provides a range of trade services to their local members and to French businesses and entrepreneurs seeking to develop their business in the Southeast of the United States.

Reaction Capital (Reaction) is a venture capital firm founded in 2019. The firm is headquartered in Palo Alto, California.

Halo-Bio RNAi Therapeutics, Inc. utilizes the novel 'Multivalent RNAi Platform' to develop multi-gene targeting products for the treatment of disease. The firm specializes in RNAi, Biopharmaceuticals, RNA Delivery and Nanoparticles. The company is headquartered in Seattle, WA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Universal Cells, Inc. develops, licenses and commercializes stem cell therapies. The company was founded by Claudia Mitchell and David Russell and is headquartered in Seattle, WA.

Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

Profilomic SA develops software solutions. It provides services in chemical, lipidomic and metabolomic analyses using liquid chromatography coupled to high resolution mass spectrometry. The company is headquartered in Boulogne-Billancourt, France.

Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France.

Kadmon Pharmaceuticals LLC manufactures and distributes pharmaceutical products. The company is headquartered in Warrendale, PA.